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The long-term stability of therapeutic protein products can be extended by freeze-drying. However, the
freeze-drying process itself has several harmful stresses. A rationalized formulation design can signifi-
cantly mitigate protein damage caused by freezing, dehydration and interfacial stresses of lyophilization
and reconstitution. Recently, a continuous spin-freeze-drying concept was proposed as a more
economical, controllable, flexible and qualitative alternative to batch freeze-drying. The purpose of this
work is to compare spin-freeze-drying to traditional batch freeze-drying with regard to protein physical
stability. The impacts of spinning, freezing and drying were investigated for both processing methods.
Herewith, the interaction between these process phases and two common rational formulation strate-
gies, (i.e. adding a disaccharide and a surfactant) was examined. Protein aggregates formed due to the
process phase stresses were characterized with particle counting techniques and size exclusion chro-
matography. It was found that spin-freeze-drying exhibited essentially identical stresses causing com-
parable aggregation in all the process phases as compared to batch freeze-drying. Moreover, there were
also analogous impacts of the formulation excipients. These observations led to the conclusion that
similar freeze-drying formulation excipients and strategies tested for decades in batch freeze-drying of
proteins can be utilized for spin-freeze-drying; in order to maintain protein stability during processing.
© 2020 American Pharmacists Association
®
. Published by Elsevier Inc. All rights reserved.Introduction
With an increasing trend in developing biopharmaceutical
products e in particular monoclonal antibodies in the last decades
and antibody-drug conjugates more recently e protein stability in
parenteral products has continued to be of great interest.1,2 As most
protein products have limited stability in aqueous solution, cold
chain distribution or freeze-drying is necessary to maintain their
product shelf-life.3,4 However, maintaining a complete cold chain
from manufacturing until patient administration is expensive and
not straightforward, as there are numerous handling steps and risks
for mishandling.5 In contrast, in a properly formulated freeze-dried
product, stability can be maintained during shipping and storage;
even with exposures to ambient temperatures.6 Nonetheless,Beer).
®. Published by Elsevier Inc. All ritraditional freeze-drying is a lengthy and costly batch-wise process.
To make the process more economical, batches are typically large,
resulting in tens of thousands to millions of vials at risk in one
process. Furthermore, there still exists a poor control of the very
influential freezing step causing significant batch-to-batch and
within batch variability.7,8
Recently, multiple alternatives to batch freeze-drying have been
proposed, in order to increase flexibility in production, significantly
reduce processing times, and to improve process control and
product quality. For example, the active freeze-drying technology
employs a conical vessel in which the product is agitated during
freezing and drying resulting in a significant increase in the subli-
mation surface area and so substantially reducing processing times.
The product temperature can be controlled through a heating/
cooling jacket of the vessel.9 Nonetheless, it is a bulk freeze-drying
technology that requires several post-process handling steps,
adding risks of loss of aseptic maintenance during filling of the
powdered product in the final primary containers. Moreover, itghts reserved.
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alternative, the research group of Pisano et al. proposed a contin-
uous concept for unit doses based on convective freezing and
radiative drying of suspended vials. Controlled nucleation is
applied, which should reduce the variability in the drying trajec-
tories and should result in more homogeneous products. This
continuous approach reduces the overall process time (up to 50%10)
by limiting all transfer and pre/post-process holding times.8,11,12
However, it still has to be shown how monitoring at the unit-
dose level, essential in continuous processing and with real-time
release, can be integrated into this concept.
The current research is focused on the continuous freeze-drying
alternative proposed and patented by Corver.13 It differs in three
main aspects compared to traditional batch freeze-drying. First,
during the spin-freezing step, the vial containing the aqueous drug
product is rotated along its longitudinal axis between 2000 and
3700 rpm to spread the liquid along the vial wall as homogeneously
as possible. Subsequently, cooling and freezing are induced using a
cold sterile gas flux until complete solidification of the drug
formulation on the vial wall. A thin frozen product layer, usually
1e3 mm in thickness is achieved. All unit doses follow a one-piece
flow methodology and are transferred between the regions in the
lyophilizer with different processing environments via load-locks,
which ensures the required pressure levels are maintained.
Finally, the heat for sublimation and desorption is supplied either
by radiation or conduction and can be tuned per unit dose to
optimize the process. Overall the continuous process can be 20 to
40-fold faster compared to traditional batch freeze-drying.14e16
However, a first GMP production continuous freeze-drying line
based on this proposed concept is still under development.
In the final prototype, radiation was chosen as the preferred
heat supply method. In contrast to conduction, radiation is a non-
contact heating method that is still efficient in vacuum condi-
tions. Moreover, the radiation method does physically not interfere
with unit-dose level process analytical techniques (PAT) such as
non-contact thermal imaging or hyperspectroscopic techniques.17
Unacceptable drug substance denaturation and aggregation,
which could result in a loss of activity and/or an immune response,18
can take place during the many stresses that occur during the entire
lyophilization and reconstitution process.19 However, in the case of
batch freeze-drying, these interactions of the process steps and the
impacts of formulation components on protein stability are well
described in literature.3,20 It is the aim of the current study to
investigate if similar stress-induced damage and stabilization
mechanisms can be observed for continuous spin-freeze-drying as
proposed by Corver.13 Herewith, first the assessment of protein
damage is made during the different processing steps of this new
technology, i.e. spinning, freezing, and drying. Next, the influence of
the addition of a surfactant and/or disaccharide is also evaluated. The
overall goal is to determine if formulation strategies currently
applicable for batch freeze-drying are also valid for the new
continuous freeze-drying technology. Several state-of-the-art parti-
cle counting techniques and size exclusion chromatography (SEC)
were used to analyze the different conditions. The applied charac-
terization techniques are synergistic in their specificity (i.e. protei-
nous aggregates versus oil droplets or air bubbles) and size range (i.e.
nm to sub-mm). A low-concentrated human intravenous immune
globulin (IVIG) formulationwas in-scope as the model protein in the
proposed study. IVIG is widely described in the literature and is
shown to be susceptible to all the stresses occurring during the
different freeze-drying phases, i.e. agitation, freezing and drying
stresses.21e23 Moreover, a low initial protein concentration is shown
to have less resistance to denaturation, attributed to a lower amount
of inter-molecular stabilisation and a higher relative propensity at
destabilizing interfaces.24Materials and Methods
Materials
Human intravenous immune globulin (IVIG) at a concentration of
100 mg/ml (GAMMAGARD LIQUID 10%, Baxter Healthcare Corpora-
tion,Westlake Village, CA, USA)was used as themodel protein for this
study. IVIG is a highly purified polyclonal antibody, with a distribution
of immune globulin G (IgG) subclasses similar to that in normal hu-
man blood plasma. High purity HPLC-grade trehalose dihydrate was
purchased from CalBiochem (Billerica, MA, USA), and D-mannitol and
polysorbate 20 (PS20) were obtained from Sigma-Aldrich (St-Louis,
MO, USA). All buffer reagents were obtained from Fisher Scientific
(Hampton, NH). Thewater used in this study was ultra-purified grade
(Millipore Simplicity, Danvers, MA, USA). Lyophilization vials (10 mL,
10R Fiolax clear) were purchase from Schott (Lukacshaza, Hungary),
and 20 mm bromobutyl 4023/50 siliconized lyophilization stoppers
were purchased from West Pharma (Exton, PA, USA).
Methods
Formulation Preparation
The commercial IVIG formulation containing 0.25 M glycine was
exchanged at 3 C for 2mM sodium citrate buffer at pH 4.623 using a
dialysis cassette with a 10.000 MWCOmembrane. Three changes of
the external solution were performed, with an excess of 300 the
volume of the external solution. Six formulations were prepared
with the IVIG at ~1 mg/ml: 2 mM sodium citrate (Buffer); 2 mM
sodium citrate þ 0.03% (w/V) polysorbate 20 (PS20); 2 mM sodium
citrate þ 5% (w/V) trehalose (Treh); 2 mM sodium citrate þ 0.03%
(w/V) PS20 þ 5% (w/V) trehalose (PS20þTreh); 2 mM sodium
citrate þ 5% (w/V) mannitol (Man) and 2 mM sodium
citrate þ 0.03% (w/V) PS20 þ 5% (w/V) mannitol (PS20þMan).
Subsequently, all these formulations were filtered using a PVDF
low-protein binding syringe filter with 100 nm pores (Millex, Cork,
Ireland). All formulations were analyzed for their IVIG concentra-
tion using the absorption at 280 nm on an Agilent 8453 UV-VIS
spectrophotometer (Santa Clara, CA, USA) with an extinction co-
efficient of 1.35 mL/mg cm25 and diluted to a final 1 mg/ml IVIG
concentration. The six formulations were stored at 3 C before
experimental use. For each processing condition and formulation,
at least three vials were filled with 2 mL solution and extensively
characterized; except for the mannitol formulations which were
only used in the freeze-drying experiments.
Rotation Experiments
The lyophilization vials were subjected to an axial rotation
similar to the spinning operation in the continuous freeze-drying
concept.14 A ZRZ-2041 overhead stirrer (Heidolph, Schwabach,
Germany) was fitted with a custom-made clamp that fits on the
20 mm vial neck. Vials were clamped and rotated along their lon-
gitudinal axis at a speed of 2200 rpm for either 10 min (Rot10min)
or overnight (RotON) as, respectively, a normal operation and a
worst-case condition. Typically, unit doses are frozen within 5 min
in the continuous concept. As for the negative control, vials were
filled and set stationary on the lab bench for 10 min (Control).
Whereas for the positive control, vials were severely agitated by an
overnight end-over-end rotation with an RKVSD Rotator (ATP,
Laurel, MD, USA) at a speed of 80 rpm (Agt). To minimize the effects
of post-processing storage, all samples were analyzed for protein
aggregates and particles on the same day that they were processed.
Freezing Experiments
Multiple freezing processes were tested. First, vials were sub-
jected to a traditional freezing protocol of a batch freeze-drying
Fig. 1. Pictures of: (a) Tight aluminium vial holder used for batch freezing (BaF), batch freeze-drying (BaFD) and conductive drying (Cond). Lyophilisation vials with stoppers are
inserted in the cylindrical holders; (b) Rotation stage used for radiative drying (Rad). Lyophilisation vials without stoppers are rotated in front of an electrical radiator.
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holder to get a uniform heat transfer (cfr. Fig. 1(a)). All sample vials
were processed together by loading them onto 20 C shelves of an
FTS Lyostar3 freeze-dryer (SP Scientic, Warminster, PA, USA). After
1 h of equilibration, the shelf was cooled at 1 C/min until 45 C,
followed by an equilibration step of 2 h at 45 C. After processing,
sample vials were stored in a 80 C freezer.
A second freezing condition employed that which is used in the
continuous freeze-drying process. Vials were spun as described in
section Rotation Experiments while being blown with approxi-
mately 50 L/min compressed air (Gas) which was cooled through a
coil submerged in a dry ice/isopropanol mixture. The temperature
of the vial was tracked with an IR650-12D infrared-thermometer
(Voltcraft, Hirschau, Germany), and upon complete solidification
(based on visual appearance) of the solution on the vial wall (within
5 min), the vial was transferred to a box with dry-ice. In another
process, vials were also spun directly in liquid nitrogen (LN); and
contents were visually solidified within one minute.
As a positive control for freeze-thawing induced protein ag-
gregation, vial contents underwent nine freeze-thaw cycles by flash
freezing the samples by immersion of vials in liquid nitrogen
(Flash9x). After each freezing cycle the vial contents were thawed
by gentle swirling in a 25 C water bath and then refroze in liquid
nitrogen.
All samples from the different freezing processes were stored in
a 80 C freezer until they were thawed for characterization. To
minimize and uniformize the effect of thawing, all samples were
thawed in a 25 C water bath (VWR Advanced Digital Shake, Rad-
nor, PA, USA) for 3 min26 with gentle swirling. Contact of the pro-
tein formulation in the vial with the vial stopper was avoided.Fig. 2. Approximate aggregate characterization size range for all the techniques used
in this study as specified by the device manufacturer. The limit of brightfield IFC is
marked with an arrow.Freeze-Drying Experiments
Three different freeze-drying methods were tested. First, a
traditional batch freeze-drying protocol (BaFD) was carried out in
the FTS Lyostar3 freeze-dryer. The vials were filled with 2 mL of
protein formulation and placed in the aluminium vial holders (cfr.
Fig. 1(a)). Freezing was executed as described in the batch section
Freezing Experiments, immediately followed by the start of pri-
mary drying for which the chamber pressure was reduced to 70
mTorr (9.33 Pa). Upon stabilization of the chamber pressure, the
shelf temperature was increased to 20 C at 2.5 C/min; this
temperature was maintained for 1400 min. Next, the shelf tem-
peraturewas raised to 33 C at 0.3 C/min to start secondary drying,
and maintained at this temperature for 240 min. At the end of the
cycle, the chamber was back-filled with dry nitrogen gas until apressure of 100 Torr (13.3 kPa) was reached. Then the vials were
stoppered.
As a second freeze-drying method (Cond), gas spin-frozen vials
(cfr. section Freezing Experiments) were dried via conduction by
loading them in the aluminium vial holders on 45 C precondi-
tioned shelves. A similar freeze-drying protocol was followed
except that the primary drying step at 20 C was limited to
495 min which was sufficient for ice sublimation from the thinner
frozen product layer.
Finally, a freeze-drying process analogous to the continuous
concept was performed (Rad) by equipping the Lyostar3 with an
electrical feedthrough, rotation stage and infrared-radiator (cfr.
Fig. 1(b)).11 Formulations in the vial were gas spin frozen (cfr. sec-
tion Freezing Experiments). The shelves were set at 20 C and
chamber pressure was reduced. When a pressure of 70 mTorr was
achieved, the power source of the radiator was turned on and fixed
to 14W. This radiator setting is rather conservative andwas defined
using the methodology described by Van Bockstal et al.16 This
methodology enables the estimation of the radiator setting based
on equipment and formulation parameters to prevent collapse of
the dried product. The vials were processed one at a time. Ten min
after convergence of the reading for the Pirani and Capacitance
vacuum gauges, when both primary and secondary drying were
assumed to be finished, the vacuum chamber was fully vented and
the vial was subsequently manually stoppered.
For the vials containing protein solution without bulking agent
(i.e. without trehalose or mannitol), a 220 nm polycarbonate filter
was fixed in the vial neck to mitigate the risk of losing large por-
tions of the fragile dried cake. For all samples, before reconstitution,
vials were slowly vented with a 32G needle pushed through the
stopper, and the dried formulations were reconstituted with the
appropriate volume of water.
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Size Exclusion Chromatography
A 400 mL aliquot of the protein solution sample was centrifuged
for 10 min at 14.000 rpm in a 5415 C Eppendorf (Hamburg, Ger-
many) centrifuge. Next, 30 mL of the supernatant was analyzed in
triplicate on an Agilent 1200 series (Santa Clara, CA, USA) chro-
matographic system equipped with a TSKgel G3000SWXL column
(TOSOH Bioscience, Tokyo, Japan), as described by Gandhi et al.25 A
mobile phase containing 400 mM sodium chloride and 200 mM
sodium phosphate at a pH 7 and a flow rate of 0.5 mL/min for
30 min was used to separate the IVIG monomer from the high-
molecular weight species (HMWS), dimer and fragments. The
relative composition of the protein species was calculated by
comparison of the eluded peak areas to the total area of the
negative control samples for each formulation. A reduction of the
total peak area in comparison to that for the appropriate negative
control was attributed to insoluble protein aggregates; i.e., aggre-
gates that were removed from the solution by the centrifugation
step. For the freeze-dried samples, all results were adjusted for
weight difference between the initial filled and reconstituted
solutions.
Flow Imaging Microscopy
Flow imaging microscopy (FIM) was applied using a FlowCam
VS1 (Fluid Imaging Technologies, Scarborough, ME, USA) which
was equipped with 10magnification and FC80FV flowcell (80 mm
depth and 570 mm width). A 950 mL aliquot of the sample was
loaded, and approximately 200 mL was used for conditioning the
system. Three consecutive measurements of 250 mL were run at
80 mL/min for each sample. The particle size and concentration in
the size range of  1 mm were recorded based on the equivalent
spherical diameter (ESD) (Fig. 2). When a particle concentration
above 1E6 was detected, the sample was diluted 10 with filtered
2 mM sodium citrate buffer and then measured. The final values
presented in the Results were corrected for the dilution.
Nanoparticle Tracking Analysis
Nanoparticle tracking analysis (NTA) utilizes the effect of light
scattering to detect individual nanoparticles, with a size range of
10e1000nm(Fig. 2). It follows their Brownianmotion to estimate the
hydrodynamic diameter. Samples were diluted 10, 50 or 100
with filtered 2 mM sodium citrate buffer and centrifuged (1 min at
14.000 rpm) to get into the 1E7 to 1E9 particle concentration range
needed for theNanoSight NS300 (Malvern Panalytical,Malvern, UK).
The NanoSight was equipped with a 488 nm excitation laser, and
samples were characterized in five replicates of 30 s of video acqui-
sition at 25 C. A syringe speed setting of 10 was used. Video
capturing and processing settings were optimized for each sample.
Imaging Flow Cytometry
Imaging Flow Cytometry (IFC) was performed as previously
described by Probst.27 Fluorescent dyes were used to differentiate
protein particles from potential oil droplets. The Proteostat dye
preferentially binds to protein aggregates and becomes fluorescent,
whereas the PMPBF2 dye has hydrophobic properties and will
therefore locate itself in the oil phase. A 90 mL aliquot of samplewas
mixed with 10 mL of dye solution, resulting in a PMPBF2 and Pro-
teostat concentrations, respectively, of 94 nM and 750 nM. All data
was acquired using the auto-sampler, whichmeasured each sample
for 2 min at a flow rate of 1.25 mL/min and automatically purged
fluidics between samples. All samples were measured in triplicate.
Unless otherwise stated, the total protein particle concentrations
based on fluorescence interaction with Proteostat are shown in the
Results.Resonant Mass Measurement
Resonant mass measurement (RMM) is a technique capable of
counting and characterizing particles in the size range ~150 nm to
5 mm (Fig. 2). It measures the buoyant mass of particles when they
pass through a micro-channel resonator. The technique can differ-
entiate air bubbles and oil droplets from protein particles since
these have opposite buoyancies. An Archimedes (Malvern Pan-
alytical, Malvern, UK) system equipped with a MicroH sensor type,
which requires a minimum concentration of 1E6 particles/mL, was
used for this study. Densities below 0.965 g/ml were assigned to
silicone oil whereas above 1.260 g/mL particles were characterized
as protein based. In the case of air bubbles counting, the density
threshold was fixed at 0.001 g/mL. A 150 mL aliquot of the centri-
fuged (1 min 14.000 rpm) supernatant was loaded and measure-
ments were executed in triplicate. In the case of air bubbles
counting, no centrifugation was used. When the particle concen-
trations were too high, 10 dilutions in filtered 2 mM sodium cit-
rate buffer were prepared and measured.
Karl Fisher titration
An electrochemical Karl-Fischer titration (KF) in duplicate as
described in the USP31 monograph 921 was applied to the freeze-
dried samples.28 The cake was dissipated with a known volume of
solvent (1/3 Formamide, 2/3 Methanol) in a closed vial and left to
equilibrate for at least 15 min. Residual moisture from the titration
vessel was removed by a pretitration and the stoichiometry of the
Hydranal (Honeywell, Charlotte, NC, USA) titrant was verified with
a known quantity of water. The water content of the solvent was
determined and subtracted from the results. To determine the re-
sidual water content, a known quantity of the resultant liquid in the
vial was injected into the titration vessel of a Mettler Toledo V30
volumetric Karl Fischer titrator (Schwerzenbach, Switzerland) and
titrated with Hydranal titrant.
Statistics
For each process phase, i.e. spinning, freezing and freeze-drying,
the results from the different characterization techniques were
evaluated by bar plots including the inter- and intra-vial standard
deviation. Furthermore, the processing and formulation effects
were determined by computing the effect compared to their cor-
responding negative control and buffer formulation, respectively.
An independent t-test (Matlab R2018a, Mathworks, Nattick, MA,
USA) between these samples was performed to evaluate the sig-
nificance of that change and are depicted by an asterisk (*) for
processing effects (e.g. BaFD Buffer vs. Control Buffer) and a hashtag
(#) for formulation effects (e.g. BaFD PS20 vs. BaFD Buffer).
Results
Rotation Experiments
After spinning vials containing 2 mL of 1 mg/ml IVIG in buffer
alone at 2200 rpm for 10 min (Rot10min) or overnight (RotON), no
reductions in monomer concentrations were observed with SEC,
compared to that in the unstressed negative control sample (Con-
trol) (Fig. 3.SEC). Furthermore, as expected, for Rot10min and
RotON no impacts of the presence of excipients were observed on
SEC results (Fig. 3.SEC). However, agitating the IVIG samples by
end-over-end rotation (Agt) in the absence of polysorbate resulted
in substantial conversion of the monomer into insoluble protein
aggregates, which was enhanced when trehalose was included in
the formulations. The presence of polysorbate in the formulations
inhibited agitation-induced protein aggregation.
Fig. 3. Multipanel with the results of the spinning experiments: (SEC): the relative fraction of protein species by size exclusion chromatography; (FIM) micro-sized particle
concentration by FlowCam; (NTA) nano-sized particle concentration by NanoSight. An asterisk (*) depicts a significant difference (p < 0.05) of the spinning method versus its own
formulation control whereas a hashtag (#) indicates significant difference (p < 0.05) of the formulation versus the buffer within the spinning method.
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FIM (Fig. 3.FIM), showed similar trends, with very low counts
(<3000/mL) for samples rotated for 10 min or overnight and no
significant differences compared to the values for unstressed con-
trol samples. Neither were effects of formulation additives
observed for these processing techniques with FIM. In contrast,
end-over-end rotation on IVIG samples resulted in an extensive
increase in the FIM particle counts. However, the addition of PS20
in the end-over-end rotated samples resulted in much lower par-
ticle counts. Furthermore, similar to the SEC results, trehalose
showed an additional destabilizing effect resulting in the highest
particle counts. When investigating the nano-particle counts by
NTA (Fig. 3.NTA), the effects of the processing methods or formu-
lation additives were comparable but less pronounced than
observed with the micro-sized particle counts by FIM.
Characterization of all the samples from rotation processing with
the RMM technique was attempted, but for the majority of samples,
no or an insignificant number of particles were detected within
10 min of acquisition. The processes led to particle counts lower than
the limit of quantification (1E6 particles), preventing analysis by
RMM. At last, IFC characterization on rotation samples was not
executed because shipping these liquid samples to the external
partner could have led to additional stresses, confounding the results.
Freezing Experiments
Upon comparing the different freezing processing methods to
the unstressed control samples with SEC (Fig. 4.SEC), a reduction in
the monomer concentration was only observed in the case of the
samples that underwent nine freeze-thaw cycles (Flash9x). The
destabilization effects of this freeze-thaw process could signifi-
cantly be reduced by adding stabilizing excipients to the formula-
tion. Adding 5% trehalose to the 1 mg/ml IVIG buffered solution led
to less protein aggregation after nine freeze-thaw cycles. Whereasadding 0.03% PS20 even had a more beneficial effect on retaining
the monomer concentration, and the combined formulation effect
of PS20 and trehalose was able to completely inhibit the monomer
loss arising during nine freeze-thaw cycles.
With the use of FIM, clear effects of all freezing processing
methods on the samples containing only IVIG in buffer (Buffer)
were observed (Fig. 4.FIM). Batch freezing (BaF p: 0.03), spin-
freezing with gas (Gas p: 0.02) or liquid nitrogen freezing (LN p:
0.09) of the buffer-only formulations resulted in similar relative
small increases in micro-particles concentrations, relative to the
level in the non-stressed control samples (Control). In contrast, the
nine freeze-thaw cycles (Flash9x) of the buffer-only sample led to a
thousand-fold increase in micro-particles, but this increase was not
found statistically significant. It has to be noted that significant
levels of air bubbles were observed in these freeze-thawed sam-
ples, which contributed to the counts from FIM and to a relatively
large standard deviation for the replicate values. Due to the very
small size of these air bubbles (2 mm) compared to the FIM limit of
detection (z0.5 mm), it was not possible to remove contributions
from air bubbles from the particle counts using robust digital filters
based on FIM particle descriptors.29 Thus, for these samples, the
relative contributions of protein particles and air bubbles could not
be distinguished in the FIM counts.
Several significant formulation effects were observed on the
micro-sized particle counts. Addition of 5% trehalose to the buffer-
only samples resulted in a noticeable cryo-protective action of IVIG
after batch or gas freezing as the particle counts were significantly
lower (BaF trehalose p: 0.046, Gas trehalose p: 0.049). The signifi-
cant stabilizing effect of addition of 0.03% PS20 was even slightly
larger in these cases (BaF PS20 p: 0.014, Gas PS20 p: 0.024).
Nano-sized particle results by NTA were again less informative
(Fig. 4.NTA) compared to the micro-sized particles by FIM. How-
ever, as NTA samples were centrifuged before measuring, poten-
tially reducing the confounding impact of the air bubbles, a
Fig. 4. Multipanel with the results of the freezing experiments: (SEC): the relative fraction of protein species by size exclusion chromatography; (FIM) micro-sized particle con-
centration by FlowCam; (NTA) nano-sized particle concentration by NanoSight; (IFC) protein aggregates concentration by FlowSight. An asterisk (*) depicts a significant difference
(p < 0.05) of the freezing method versus its own formulation control whereas a hashtag (#) indicates significant difference (p < 0.05) of the formulation versus the buffer within the
freezing method.
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cles was observed, compared to the impacts of the other freeze-
thawing processes. Moreover, the protective effects of adding
trehalose (p: 0.024) or PS20 (p: 0.001) after nine-freeze thaw cycles
were clearly visible in the results obtained from NTA (Fig. 4.NTA).
All frozen samples were also characterized by IFC which had a
broad characterization size range (0.1e100 mm) and was specific for
protein aggregates due to the fluorescent dye staining.27 Thus, re-
sults were not confounded by counts due to air bubbles. Clear in-
creases in the protein particles counts were observed for the
samples without surfactant for all freezing conditions, in compar-
ison with the non-stressed control samples. Analogous to the other
characterization techniques, samples without surfactant after nine
freeze-thaw cycles had higher particle counts with IFC compared to
the other freezing processing methods (Fig. 4.IFC). For all freezing
processing methods, a remarkably strong stabilization of IVIG was
observed in the IFC data for samples containing 0.03% PS20
compared to the buffer-only or trehalose-only samples (p: 8E-4 till
0.01). A significant stabilization effect of adding 5% trehalose to the
buffer-only samples was also visible in Fig. 4.IFC for samples frozen
by liquid nitrogen (LN p: 0.016) or undergoing nine freeze-thaw
cycles (Flash9x p: 0.007).Freeze-Drying Experiments
During the freeze-drying experiments, a comparison was made
between batch freeze-drying (BaFD) and spin-freeze-drying via a
conductive (Cond) or a radiative (Rad) method using the 1 mg/ml
IVIG solutions. Furthermore, the formulation effects of adding PS20,
trehalose (Treh) or mannitol (Man) were also evaluated. Results
from the SEC analyzes (Fig. 5.SEC) showed similar drops in mono-
mer concentration after processing the buffer-only formulations
with all freeze-drying methods relative to the levels measured in
unstressed control samples. Concomitant with monomer loss was a
considerable increase in the insoluble aggregate fraction. The
presence of 5% trehalose in the formulation did not lead to a sig-
nificant increase in the monomer concentration. Addition of 5%
mannitol led to an increased freeze-drying stress as substantially
more monomer species were converted into HMWS or insoluble
aggregates (20e28%) than in samples with buffer alone. Adding
0.03% PS20 to the buffer-only or trehalose formulations led to
almost complete inhibition of the destabilization of all freeze-
drying methods, evidenced by the limited monomer concentra-
tion losses (only up to ca. 2%) compared to the unstressed control
samples. However, adding PS20 to the mannitol formulations led to
Fig. 5. Multipanel with the results of the freeze-drying experiments: (SEC): the relative fraction of protein species by size exclusion chromatography; (FIM) micro-sized particle
concentration by FlowCam; (NTA) nano-sized particle concentration by NanoSight; (IFC) protein aggregates concentration by FlowSight. An asterisk (*) depicts a significant dif-
ference (p < 0.05) of the freeze-drying method versus its own formulation control whereas a hashtag (#) indicates significant difference (p < 0.05) of the formulation versus the
buffer within the freeze-drying method.
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nificant monomer losses (up to 18%) observed when comparing
with the control PS20þMan sample.
Micro-sized particle data observed with FIM (Fig. 5.FIM) showed
high concentrations (>1E6 particles/ml) for the trehalose- and
mannitol-only formulations after batch (BaFD) and conduction
(Cond) freezing-drying. However, these results could be confounded
by reconstitution effects such as foaming and formation of long-
lasting air bubbles which were visually observed and confirmed by
the positive buoyancy measurements of air by RMM (Fig. 6.RMMþ).
Addition of 0.03% PS20 to these formulations greatly reduced the
reconstitution and/or freeze-drying destabilization as significantly
less micro-sized particles were observed (p: 0.006 till 0.047). Radi-
ative drying also led to a significant increase in micro-sized particles
compared to the unstressed control samples (p: 0.001 till 0.041), but
the freeze-drying and reconstitution destabilization was generally
less pronounced compared to the other drying techniques.
NTA data (Fig. 5.NTA) showed a clear increased formation of
nano-sized particles for the mannitol formulations in all processing
methods compared to the other formulations. Furthermore, the
strong inhibition of freeze-drying and/or reconstitution effects ofPS20 was also observed in the NTA data. Addition of 0.03% PS20 to
either buffer-only, trehalose or mannitol led to substantially fewer
nano-sized particles after processing with all the freeze-drying
methods (p: 0.0004 till 0.025). Polysorbate could be responsible
for lowering the nano-sized proteinaceous particles and/or the
stable nanobubbles.30 However, the NTA technique is not capable of
differentiating between these populations.
From the IFC data for freeze-dried and reconstituted samples,
two populations could be extracted based on the preferential dyes.
The protein aggregates population (Fig. 5.IFC) e not confounded by
the air bubbles forming upon reconstitution e displayed a signifi-
cantly increased count after freeze-drying of the buffer-, trehalose-,
and mannitol-only formulations with all processing methods
(BaFD, Cond and Rad) compared to their unstressed control (p: 1E-5
till 0.004). The remarkably strong stabilization effect by adding
0.03% PS20was also clearly visible in Fig. 5.IFC (p: 3E-4 till 0.014). In
addition, a second oil particulate population was plotted in
Fig. 6.IFC-Oil. The plot displays sizeable amounts of oil droplets,
presumably silicone oil from vial stoppers, in the cakes of batch
(BaFD) and conduction (Cond) dried samples. Remarkably, a higher
concentration was observed in the presence of PS20.
Fig. 6. Multipanel with additional results of the freeze-drying experiments: (KF) Re-
sidual moisture by Karl-Fisher; (RMMþ) Positive buoyancy for air bubbles by Archi-
medes; (IFC Oil) The oil particulate population from the FlowSight data-set by staining
with the PMPBF2 dye.
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processing methods and for all formulations were measured and
displayed in Fig. 6.KF. Two distinct groups were identifiable. When
a bulking agent (trehalose or mannitol) was present in the
formulation, residual moisture content by Karl-Fisher was below
1%. In opposition, without bulking agent the desorption process
stabilized at considerable higher moisture contents (3.8 till 5.7%).
Furthermore, PS20 did not have a significant impact on the results.
Lastly, the temperature of the cakes at the end of secondary
drying, measured by an infrared thermometer, was comparable for
all freeze-drying processing methods (i.e. BaFD, Cond and Rad) and
varied between 30 and 37 C.Process Phases
The trends across the process phases (i.e. Control, Spinning,
Freezing and Drying) applied in batch freeze-drying (BA) and spin-
freeze-drying by conduction (COND) and radiation (RAD) are
plotted in Fig. 7. The SEC overview (Fig. 7a) displays no major
impact of the spinning or freezing step for batch, conductive and
radiative freeze-drying. Significant drops in monomer concentra-
tion were only observed after drying the buffer-only (blue plots)
formulations in all three cases. In the case of batch and conductive
drying, the trehalose-only formulations (yellow plots) also dis-
played a similar drop in monomer concentration whereas addition
of 5% trehalose in the case of radiative drying seemed to have a
stabilizing effect. Adding 0.03% PS20 to the formulations (orange
and purple plots) appeared to inhibit the destabilization effects of
all the freeze-drying methods.
No significant increase in nano- and micronized particle con-
centration (Fig. 7b-c) was detected for a vial rotation of 10 min at2200 rpm (Spinning). FIM as well NTA and IFC (Fig. 7b-d) showed a
similar increase in particle count after freezing the buffer-only
formulation for both the batch- as spin-freezing processing
method. Complete stabilization by adding 0.03% PS20was observed
in all particle counting techniques for batch- as well as spin-
freezing since no significant increase was visible compared to the
preceding process phase.
Batch freeze-drying (BA) and conductive drying (COND) of the
spin-frozen samples showed very similar trends in the particle
counting data (Fig. 7b till d) for all formulations. The buffer-only
and trehalose-only formulation showed the biggest increases in
particle counts. In the case of radiative drying, a lower level of
particles was observed for the buffer-only and trehalose-only
formulation compared to batch or conductive drying. However,
addition of 0.03% PS20 also led to a lower concentration of particles
in all the counting techniques, and quite similar levels were
observed between all the drying methods.
Discussion
IVIG seemed to be an appropriate model-protein for this study
as it was susceptible to aggregation and particle formation by all
three stresses tested, i.e. agitation, freezing and freeze-drying. This
was evidenced by the positive controls during the rotation and
freezing experiments (Agt and Flash9x) showing a considerable
decline in monomer concentration due to aggregation. Further-
more, in the case of the freeze-drying experiments all processing
methods (BaFD, Cond and Rad) showed significant protein desta-
bilization in the buffer-only and mannitol formulations. These re-
sults are in accordance with those from previous studies in which
IVIG was utilized for investigating the effects of these specific
stresses.21e23
The lack of destabilisation effects during the Rot10min and
RotON rotation experiments was expected since no major air-water
interface surface renewal is present with an axial rotation of a
cylinder. This confirms the findings of Lammens et al.31 and proves
that the spinning phase does not pose additional risks to the sta-
bility of IVIG. Clear effects of formulation additives were observed
with the Agt samples. PS20, a non-ionic surfactant, showed a strong
stabilizing impact attributed to its well-documented interfacial
effects.32 Surfactants compete with protein molecules for adsorp-
tion to the air-water interface, effectively inhibiting protein film
formation at the interface and the resulting formation of aggregates
and particles during film rupture.23,33
In contrast, trehalose showed a slight destabilizing effect during
agitation stresses, consistent with earlier results from Serno et al.34
and Chou et al.35 where sucrose was used as the excipient. This
behavior might be surprising as non-reducing disaccharides (i.e.
trehalose, sucrose) are mainly used as stabilizing agents in freeze-
drying. The stabilizing effects during freezing are due to the
Timasheff mechanism which favors lower protein surface areas of
exposure to solvent (due to preferentially excluded solutes) and
thus inhibits partial unfolding during freezing. Nonetheless, these
excipients also increase the surface tension of the air-liquid inter-
face which might promote adsorption of protein molecules to that
air-water interface. The surface tension effect of trehalose in com-
bination with the extensive renewal of the air-liquid interface
occurring during the end-over-end agitation could cause the
additional aggregation of IVIG in the trehalose sample (Agt Treh)
compared to the buffer-only sample (Agt Buffer); as observed with
SEC and FIM (Fig. 3).
Sub-visible particle counting techniques proved to be very
useful in evaluating the impact of the different freezing processing
methods as SEC was not sensitive enough to detect significant mass
changes except for the nine consecutive freeze-thaw condition
Fig. 7. Multipanel depicting the trends across the processing phases with (a) the monomer concentration on SEC; (b) the micro-sized particles on FIM; (c) the nano-sized particles
on NTA and (d) the protein aggregate count on IFC. The different colors (Blue: Buffer; Red: PS20; Yellow: Trehalose and Purple: PS20þTrehalose) represent the formulations whereas
the signs show the processing methods (circle: Batch; cross: Radiation and asterisk: Conduction freeze-drying). Errorbars show the inter-vial standard deviation.
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able to detect and quantify different levels of sub-visible particles
due to freeze-thaw and formulation effects.36 They showed a strong
stabilization effect of adding 0.03% PS20 to buffer-only and treha-
lose samples after freezing. Since PS20 is known to reduce inter-
facial stresses, it is clear that freezing will lead to the formation of
an additional destabilizing ice-liquid interface.3,19,26,37 Moreover,
the FIM data displayed a clear cryostabilization effect of trehalose
on the micro-sized aggregates, presumably due to the Timasheff
mechanism. This cryo-stabilization effect was also apparent in the
nano-particles (NTA) and IFC data when freezing stresses were
enlarged by nine consecutive freeze-thaw cycles (Flash9x).
Spin freezing (either by gas or LN) showed a similar destabili-
zation effect as batch freezing, evidencing an equal processability of
batch- and spin-freezing in regard of protein stability. Moreover,
there was a robustness of the effect of the freezing rate in the case
of spin-freezing on IVIG stability as demonstrated by the similarity
of results between Gas and LN.
The air bubbles confounding the results of the batch and
conductive freeze-drying experiments most likely originated from
micro-voids formed during the drying process in the matrix of the
bulking agent as ice crystals sublimated.30 These air bubbles also
cause an extra air-liquid interface upon reconstitution and could
increase the protein particle count itself, evidenced by the IFC data
and previously reported by Zhou et al.30 Additionally, for the radia-
tive dried samples, a slightly lower IVIG destabilizationwas observed
after adding 5% trehalose to the buffer-only samples on SEC and the
particle counting techniques (Fig. 7) and little to no air bubbles were
observed after radiative drying (Fig. 6.RMMþ). These observations
would suggest that the destabilizing effect of the air bubbles is more
pronounced than the lyo-protective action of trehalose.The lack of a significant stabilizing effect observed by adding 5%
trehalose could also originate in the fact that citrate was used in the
pH-buffer. Citrate is an organic molecule that can form hydrogen
bonds to stabilize IVIG, using the water replacement theory, as
earlier described by Izutsu et al.38 Moreover, when comparing the
KF results, the buffer- and PS20-only formulations have a consid-
erably higher residual moisture content (around 5% versus < 1%).
Jiang et al.37 showed a relation of the residual moisture of a freeze-
dried cake with protein stability. The higher residual moisture
content of the buffer-only samples could perhaps have led to a
slightly more intact protective hydration layer compared to the
trehalose samples. The lower residual moisture content of the
trehalose samples might therefore lead to slightly higher aggregate
counts. The huge difference in residual moisture when adding a
bulking agent most probably originates from a quite different
desorption coefficient of the bulking agent compared to a dominant
protein matrix. As all formulation samples within one freeze-
drying technique were processed using a similar protocol, a
different desorption coefficient would lead to a difference in re-
sidual moisture. Another parameter causing the residual moisture
differences could be the final desorption temperature, but after
measuring the product temperature by with an infra-red ther-
mometer during unloading of the vials, it was found to be similar
for all freeze-drying samples.
In the case of freeze-drying with mannitol, dramatic losses of
monomer concentration and increases in particle counts were
observed in all freeze-drying methods. This could perhaps also be
attributed to the air-bubble formation during reconstitution.
However, a formulation with an excess of mannitol will also
encounter crystallization of mannitol during freeze-drying. This
would result in an additional phase next to the amorphous phase
B. Vanbillemont et al. / Journal of Pharmaceutical Sciences xxx (2020) 1-1110containing the protein.39 Moreover, an extra extensive crystal-
amorphous solid interface appears which could perhaps attribute
to interfacial destabilization stresses of the protein molecules.
Another striking observation comes from the IFC data where the
presence of oil in the batch freeze-dried (BaFD) and conductive
freeze-dried (Cond) cakes were observed; especially in the for-
mulations containing PS20. These oil droplets most likely originate
from the siliconized stopper which was located in the neck of the
vial for these two freeze-drying methods. In the continuous spin-
freeze-drying concept using radiative drying (Rad), the vial is
only equipped with a stopper after freeze-drying likely explaining
the very low counts for the radiative drying samples. The mecha-
nism of the migration of the silicone oil from the lyophilization
stopper to the freeze-dried cake is unknown and should be inves-
tigated in more detail. However, the bulk and reconstituted solu-
tion did not touch the siliconized stopper, and in the case of
conductive drying, the stopper was only fitted after freezing. These
facts would suggest that themigration should have happened along
the glass vial during vacuum drying. Moreover, the colloidal sta-
bility of silicone oil droplets in a pharmaceutical solution is known
to be dependent on the formulation additives. Addition of excipi-
ents that increase the surface tension, such as sucrose or trehalose,
will increase the silicone oil coalescence rate leading to fewer but
larger droplets while surfactants stabilize emulsions and therefore
will reduce the coalescence rate.40 The higher oil droplet counts
observed by IFC for the freeze-dried samples containing PS20 could
be explained by the lower silicone oil coalescence rate in the
reconstituted solution leading to more but smaller droplets.
Conductive freeze-drying (Cond) showed comparable trends for
protein aggregation and particle formation as batch drying (BaFD)
with all formulations, even with the considerably shorter drying
phase. As no significant differences were also observed between
spinning 10 min (Rot10min) versus the unstressed control and
between gas spin-freezing (Gas) versus batch freezing (BaF) it
would indicate that both batch as continuous processing are quite
similar with regard to stresses to proteins and impacts of excipients
on protein stabilization. The radiative drying as applied in the
continuous concept has even a much lower total processing time,
i.e. hours instead of days, compared to batch processing. None-
theless, also this did not lead to additional stresses because similar
trends in protein aggregation and particle formationwere observed
for the different formulations. The slight differences observed in
radiative drying towards the other drying methods, could possibly
be attributed to a lack of air bubbles upon reconstitution. In the
fully optimized formulation (i.e. PS20þTrehalose) little to no dif-
ferences were found between the three drying scenarios. None-
theless, the origin of the lower propensity of air bubbles in radiative
drying compared to batch or conductive drying has to be investi-
gated further. As the freezing phase was similar for radiative and
conductive drying; SEM, BET, or micro-computed tomography of
the pores in the dried cake could reveal if thereweremorphological
pore differences caused by drying, explaining these results.
Conclusion
When comparing traditional batch processing versus the
continuous concept, identical effects were observed from the
formulation conditions and process steps. Several stresses origi-
nated from freezing and freeze-drying. However, using an opti-
mized formulation, these effects can be greatly reduced or even
fully inhibited. This leads to the conclusion that in terms of protein
stability identical formulation and process development ap-
proaches and strategies are applicable for the continuous spin-
freeze-drying technology as have been applied successfully to
traditional batch freeze-drying for decades.CRediT authorship contribution statement
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